Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie K Jones

Showing results (51-60 of 157) with videos related to

Pageof 16
Sort By:
ACS Chemical Neuroscience|July 4, 2019
Acute Negative Allosteric Modulation of M<sub>5</sub> Muscarinic Acetylcholine Receptors Inhibits Oxycodone Self-Administration and Cue-Induced Reactivity with No Effect on AntinociceptionRobert W Gould, Barak W Gunter, Michael Bubser, et al.
ACS Chemical Neuroscience|November 27, 2018
Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain ModelsKristopher K Abney, Michael Bubser, Yu Du, et al.
ACS Chemical Neuroscience|September 20, 2011
(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addictionCraig W Lindsley, Brittney S Bates, Usha N Menon, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2022
Discovery of a potent M<sub>5</sub> antagonist with improved clearance profile. Part 2: Pyrrolidine amide-based antagonistsDouglas L Orsi, Andrew S Felts, Alice L Rodriguez, et al.
ACS Medicinal Chemistry Letters|January 12, 2013
Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic ActivityYa Zhou, Jason T Manka, Alice L Rodriguez, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteresDouglas J Sheffler, Michael T Nedelcovych, Richard Williams, et al.
Bioorganic & Medicinal Chemistry Letters|September 23, 2008
Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moietiesThomas M Bridges, Ashley E Brady, J Phillip Kennedy, et al.
ACS Chemical Neuroscience|May 21, 2013
Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addictionRussell J Amato, Andrew S Felts, Alice L Rodriguez, et al.
Pageof 16

Showing results (51-60 of 157) with videos related to

Sort By:
Pageof 16
ACS Chemical Neuroscience|July 4, 2019
Acute Negative Allosteric Modulation of M<sub>5</sub> Muscarinic Acetylcholine Receptors Inhibits Oxycodone Self-Administration and Cue-Induced Reactivity with No Effect on AntinociceptionRobert W Gould, Barak W Gunter, Michael Bubser, et al.
ACS Chemical Neuroscience|November 27, 2018
Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain ModelsKristopher K Abney, Michael Bubser, Yu Du, et al.
ACS Chemical Neuroscience|September 20, 2011
(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addictionCraig W Lindsley, Brittney S Bates, Usha N Menon, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2022
Discovery of a potent M<sub>5</sub> antagonist with improved clearance profile. Part 2: Pyrrolidine amide-based antagonistsDouglas L Orsi, Andrew S Felts, Alice L Rodriguez, et al.
ACS Medicinal Chemistry Letters|January 12, 2013
Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic ActivityYa Zhou, Jason T Manka, Alice L Rodriguez, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: development of a [3.3.0]-based series and other piperidine bioisosteresDouglas J Sheffler, Michael T Nedelcovych, Richard Williams, et al.
Bioorganic & Medicinal Chemistry Letters|September 23, 2008
Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moietiesThomas M Bridges, Ashley E Brady, J Phillip Kennedy, et al.
ACS Chemical Neuroscience|May 21, 2013
Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addictionRussell J Amato, Andrew S Felts, Alice L Rodriguez, et al.
Pageof 16